Avidity Biosciences, Inc. (RNA)

Market Cap	3.43B
Revenue (ttm)	8.93M
Net Income (ttm)	-369.22M
Shares Out	120.54M
EPS (ttm)	-3.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,159,816
Open	28.25
Previous Close	28.40
Day's Range	27.71 - 29.46
52-Week Range	21.51 - 56.00
Beta	0.95
Analysts	Strong Buy
Price Target	68.00 (+138.93%)
Earnings Date	Aug 8, 2025

About RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company’s pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystro...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 391
• Stock Exchange: NASDAQ
• Ticker Symbol: RNA
• Website: https://www.aviditybiosciences.com

Financial Performance

In 2024, Avidity Biosciences's revenue was $10.90 million, an increase of 13.99% compared to the previous year's $9.56 million. Losses were -$322.30 million, 51.9% more than in 2023.

Analyst Summary

According to 14 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price target is $68.0, which is an increase of 138.93% from the latest price.

Price Target

$68.0

(138.93% upside)

Analyst Consensus: Strong Buy